Ubs Oconnor LLC Larimar Therapeutics, Inc. Transaction History
Ubs Oconnor LLC
- $1.51 Billion
- Q4 2024
A detailed history of Ubs Oconnor LLC transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 188,543 shares of LRMR stock, worth $601,452. This represents 0.05% of its overall portfolio holdings.
Number of Shares
188,543Holding current value
$601,452% of portfolio
0.05%Shares
9 transactions
Others Institutions Holding LRMR
# of Institutions
125Shares Held
66.8MCall Options Held
500KPut Options Held
61.2K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$67.7 Million2.01% of portfolio
-
Janus Henderson Group PLC London, X06.44MShares$20.6 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$19.3 Million0.37% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.65MShares$14.8 Million7.6% of portfolio
-
Goldman Sachs Group Inc New York, NY4.15MShares$13.2 Million0.0% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $138M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...